TITLE

DSM Biologics and Crucell Enter Licensing Deal

AUTHOR(S)
Bryner, Michelle
PUB. DATE
August 2007
SOURCE
Chemical Week;8/1/2007, Vol. 169 Issue 26, p19
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop undisclosed antibodies. The companies will also evaluate the potential for a joint collaboration to develop sugar structures on recombinant antibodies using a proprietary technology of LFB.
ACCESSION #
26201339

 

Related Articles

  • Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies.  // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p134 

    The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...

  • World Briefs.  // Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22 

    The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM...

  • DSM and Crucell license antibody technology to Sartorius.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16 

    The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...

  • News Watch.  // European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25 

    Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring...

  • MorphoSys Signs Cooperative Agreements.  // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166 

    The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...

  • Pharmaceuticals & fine chemicals.  // Chemical Week;1/1/2003, Vol. 165 Issue 1, p33 

    Presents news briefs on the chemical industry as of January 1, 2003. License deal signed by DSM Biologics with Crucell; Acquisition of the patents of Novozymes relating to the production of a recombinant enzyme for pharmaceutical applications by Solvay.

  • Crucell signs licensing deal. Tyler, Alan // European Chemical News;6/14/2004, Vol. 80 Issue 2104, p29 

    Reports on the research licensing deal signed by Dutch biotechnology player Crucell with PanGenetics. Significance of the deal to PanGenetics; Payment and annual maintenance fees to be received by Crucell and DSM Biologics; Description made by PanGenetics on itself.

  • Pharma CAPSULES.  // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p106 

    The article offers news briefs related to the pharmaceutical industry. A new facility called PERCIVIA PER.C6 Development Center was opened by biotechnology company Crucell NV and technology partner DSM Biologics. A high-speed packaging line is planned by contract manufacturer Surefil LLC to...

  • Innovations.  // ICIS Chemical Business;1/15/2007, Vol. 2 Issue 49, p30 

    This section presents two international news briefs related to the chemical industry. A license agreement was signed by DSM Biologics and Dutch biotechnology partner Crucell with Portuguese biotechnology company Biotecnol and its U.S. subsidiary. Fluoropolymer producer Dyneon has bought...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics